Using Nominal Group Technique With Human-Centered Design to Inform Preimplementation Planning for Combined Rapid-Start Initiation of Antiretroviral and Opioid Agonist Therapies in People Who Inject Drugs With HIV in Ukraine
Related Experiment Video
Updated: Apr 28, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Ann E Johnson1,2,3,4,5,6,7,8, Mary Tate1,2,3,4,5,6,7,8, Myroslava Filippovych1,2,3,4,5,6,7,8
1Ann E. Johnson, PhD, is an MD Candidate, Yale School of Medicine and Yale School of Public Health, New Haven, Connecticut, USA.
Abstract:
International guidelines recommend rapid-start antiretroviral therapy (RS-ART) for people with HIV. Guidance for implementing RS-ART among people who inject drugs (PWID), a population often denied equitable treatment due to stigma and rights violations, remains limited. Using human-centered design, barriers and facilitators to combined RS-ART and opioid agonist therapy initiation in Ukraine were explored, where HIV is concentrated among PWID with opioid use disorder. Using nominal group technique, a human-centered design method involving client input, five focus groups (6-12 participants each and 42 participants total) with PWID with HIV in four Ukrainian cities most affected by HIV were conducted. Responses were rank-ordered and grouped using NVivo along the socioecological model. The most common barriers were organizational, including nonintegration of ART and opioid agonist therapy services (45%), followed by individual (22%), such as fear of withdrawal symptoms, policy/regulatory (20%), including the national addiction registry, and relationship (13%) barriers, including pervasive stigma. Solutions focused on equity, promoting behavioral design interventions like choice architecture, nudging, and message framing.
Related Concept Videos
Retrovirus Life Cycles
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Dosage Regimen Designs: Nomograms and Tabulations
Drug Discovery: Overview
Dosage Regimens: Designs and Approaches

